S&P 5007,691▲ 0.41%Nasdaq26,431▲ 1.11%Dow Jones51,966▼ 0.07%Nasdaq 10029,529▲ 1.17%VIX18.44▼ 7.75%US Dollar101.97▲ 0.13%Gold spot4,165▲ 0.21%WTI spot101.91▲ 1.04%
Home › S30 › Research report
← S30 page
XStocksXray
Market X-Ray report · 19 October 2026

Solutions 30 SE (S30)

Euronext Paris · France · prices in EUR · close of 19 Oct 2026

Key indicators

Last closeEUR 0.420
52-week range0.408 – 1.058
Return, 1 month / 3 months−18.1% / −22.7%
Return, 1 year / 3 years−59.6% / −74.0%
TrendBelow its 200-day average
RSI (14)33
Volatility (1 year)46.2%
Worst drawdown (1 year)-60.2%
Average daily value traded0.23M EUR
Dividend yield–

Market X-Ray price-based

28/ 100 · High confidence · ahead of 17% of stocks on this exchange
Trend11
Momentum16
Stability (higher is calmer)30
Liquidity70
Income–

Five-year price chart navy: price · brown: 200-day average

-0.052.094.236.378.502021-112023-022024-052025-072026-10

About the company

Solutions 30 provides technical installation and support services for telecom, energy and digital equipment. Its field technicians connect and maintain broadband, television and energy systems for telecom operators, utilities and retailers, and it also handles payment terminals and other electronic devices. The company is based in Luxembourg and operates across several European countries, serving both large corporate clients and smaller businesses through local service teams.

Solutions 30 SE trades under the code S30 on the Euronext Paris in France, with its price quoted in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Solutions 30 SE (S30) trades on the Euronext Paris in France. It last closed at EUR 0.420 on 19 October 2026.

Its price-based Market X-Ray is 28 out of 100 (a weak price profile), ranking 519 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price fell 59.6% and over the last three months it fell 22.7%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Solutions 30 SE (S30)

The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris

Lens and metricValueScoreReading
Trend11 · WeakBelow its long-term averages and far from its highs.
Above 200-day average-37.4%
From 52-week high-59.4%
Momentum16 · WeakLagging most stocks on this exchange.
3-month return-22.7%
6-month return-30.6%
12-month return, skipping the last month-50.7%
Stability (higher is calmer)30 · WeakVolatile, with deep drawdowns.
Volatility, 1 year (lower is calmer)46.2%
Worst drawdown, 1 year (smaller is calmer)-60.2%
Liquidity70 · StrongTrades actively.
Average daily value traded0.23M EUR
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Liquidity: Trades actively.

Weak spots

  • Trend: Below its long-term averages and far from its highs.
  • Momentum: Lagging most stocks on this exchange.
  • Stability (higher is calmer): Volatile, with deep drawdowns.

Returns

1 week−2.7%
1 month−18.1%
3 months−22.7%
6 months−30.6%
1 year−59.6%
3 years−74.0%
5 years−94.3%

Signals

50-day / 200-day average0.522 / 0.671
Golden / death cross (60 days)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.024

Technical summary

DailyStrongly bearish3 bullish · 1 neutral · 12 bearish
WeeklyStrongly bearish1 bullish · 0 neutral · 11 bearish
MonthlyStrongly bearish0 bullish · 1 neutral · 7 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 20 Oct 2026